Helle-Brit Fiebrich-Westra

Helle-Brit Fiebrich-Westra

Auto-generated profile, based on publicly available information

Helle-Brit Fiebrich-Westra

Isala Oncology Center, Isala Hospital, Zwolle, THE NETHERLANDS

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
ESE.G.M. Steenhuis
E.G.M. Steenhuis
ISIvonne johanna harriette Schoenaker
Ivonne johanna harriette Schoenaker
JGJ.W.B. de Groot
J.W.B. de Groot
HFH.B. Fiebrich
H.B. Fiebrich
JGJ.C. de Graaf
J.C. de Graaf
WCW.H. de Vos Tot Nederveen Cappel
W.H. de Vos Tot Nederveen Cappel

27 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LLLina Helena Lankhorst
Lina Helena Lankhorst
HFHelle-Brit Fiebrich-Westra
Helle-Brit Fiebrich-Westra
IHIrene E.G. van Hellemond
Irene E.G. van Hellemond
NGNoor Giesbertz
Noor Giesbertz
LKLizet E. van der Kolk
Lizet E. van der Kolk
OHOlga Husson
Olga Husson
Purpose: Adolescents and young adults (AYAs; aged 18–39 years at cancer diagnosis) with poor-prognosis cancer may benefit from whole-genome sequencing (WGS) to optimise treatment selection and refine diagnosis. Given their distinct life phase, AYAs may have specific expectations, motivations, and information needs regarding WGS. This study explores AYAs' knowledge, expectations, motivations, and communication preferences prior to disclosure of WGS results.Methods: This study presents a cross-sectional analysis of baseline data from the longitudinal multicentre mixed-methods GEN-impact-AYA study, collected prior to disclosure of WGS results. Participants (N = 105) completed items assessing knowledge and expectations of WGS; factors influencing the decision to pursue WGS; attitudes toward WGS; perceived advantages and disadvantages; and satisfaction with WGS and the information provided.Results: Overall, AYAs were satisfied with their decision to have WGS. Main motivations included its potential to support treatment decisions (77.7%) and a desire to help future patients (53.4%). The majority (59.0%) had good knowledge of WGS. AYAs estimated, on average, a 60.5% probability that WGS would contribute to their diagnosis or treatment, on a scale from 0 (very unlikely) to 100% (very likely). However, many AYAs reported receiving limited information on the likelihood of treatment implications and potential germline findings.Conclusion: AYAs with poor-prognosis cancer receiving paired tumour–normal WGS recognise its potential to guide treatment decisions and contribute to future care. However, their expectations often reflect hope and may exceed the realistic clinical yield of WGS. Clinicians should clearly communicate tumour-specific implications of WGS, including potential germline findings. Given the high information-seeking behaviour among AYAs, directing them to trustworthy (online) resources before disclosure of WGS results is essential.

30 July 2026 in Drugs & Therapy Perspectives
Verified
Journal Article
Open access
PDF file
HFH. B. Fiebrich-Westra
H. B. Fiebrich-Westra
CHC. J. P. Op ’T Hoog
C. J. P. Op ’T Hoog
RBR. M. Brohet
R. M. Brohet
EBE. Boerrigter
E. Boerrigter
ESE. J. Smolders
E. J. Smolders
Background Paclitaxel is widely used in breast cancer treatment but is associated with hypersensitivity reactions (HSRs), historically prompting routine premedication with corticosteroids, histamine 2 (H2)- and histamine 1 (H1)-antagonists. First-generation H1-antagonists such as clemastine or diphenhydramine frequently cause sedation and anticholinergic adverse effects, whereas second-generation agents such as cetirizine or loratidine have a more favorable safety profile. Optimizing premedication regimens may reduce treatment burden and improve patient safety. Objective To evaluate the comparative safety and effectiveness of cetirizine versus clemastine in preventing paclitaxel induced HSRs in patients with breast cancer. Methods A multicenter prospective observational cohort study was conducted across three Dutch hospitals. Female patients receiving weekly paclitaxel following dose dense doxorubicin/cyclophosphamide were included. Premedication consisted of either oral cetirizine or intravenous clemastine according to institutional protocols. HSRs during the first two paclitaxel doses were graded using CTCAE v5.0. Premedication-related adverse events were assessed using a structured nurse-administered questionnaire. Results Among 100 patients (50 per cohort), HSR incidence was identical: 8% in both groups, predominantly grade 1, with no severe reactions and no treatment discontinuations. By contrast, adverse events were markedly more frequent with clemastine (80%) than with cetirizine (10%), driven predominantly by higher rates of sedation and drowsiness in the clemastine group. Conclusions Cetirizine appeared to provide efficacy comparable to clemastine in preventing paclitaxel induced HSRs, while markedly reducing sedative adverse effects. Its oral administration also streamlines clinical workflows. These findings may support cetirizine as a safer, more patient centered H1-antagonist option for paclitaxel premedication and warrant consideration in efforts to optimize supportive care protocols.